Entries by Thomas Gabrielczyk

Abingworth raises $356m for new CCD fund

Raising $356m through a new Clinical Co-Development Co-Investment Fund (CCD-CIF), Carlyle-subsidiary Abingworth has extended its capital base for late-stage clinical bio-pharma programmes. 

   

Your Portable Rapid Test Reader

The Future of Diagnostic: Portable. Everywhere. Every time. The ESEQuant® Go offers new possibilities for home and self-testing. Take your healthcare into your own hands.

Challenges in the central lab

Clinical trials have to be coordinated as a safe process where monitoring, analytics and handling of patient samples is streamlined – even cross oceans. German MLM Medical Labs is quickly establishing itself as an emerging central and specialty lab in the U.S.

Efficacy evaluation

Antibody drugs including monoclonal antibodies (mAb), bispecific antibodies, antibody-drug conjugates (ADCs), and nanobodies have sparked a new surge in research and development.

Xlife Sciences AG acquires 20% stake in 4D Lifetec AG

In a significant financial milestone, Xlife Sciences AG invests CHF23.3m in 4D Lifetec AG. With the agreement signed today, Xlife Sciences is not only bringing in a direct cash investment, but also an AI software developed specifically for 4D Lifetec, which will massively expand the functionality of the 4D Lifetest in the field of digital health. The strategic investment marks a significant turning point in the healthcare industry as it combines financial strength with cutting-edge technology to revolutionize early cancer detection.

4D Lifetec, a pioneer in early cancer detection, owns an immuno-oncology biomarker that has proven its high sensitivity already in cancer stages I and II in numerous clinical studies. The easy-to-use IVD certified blood test enables a unique high-throughput analysis of patient samples, providing a powerful data set that now becomes accessible to train AI through the transaction. Backed up with a substantial investment, 4D Lifetec gains a doorway to innovative AI that will redefine the landscape of cancer diagnosis and access to the digital health network of Xlife Sciences. In addition, the deal also provides the financial strength necessary for implementation.

Zurich-based Xlife Sciences is a publicly traded accelerator and investor company dedicated to addressing unmet medical needs and improving the quality of life through innovative healthcare solutions. Xlife Sciences was among the first to recognize the importance of artificial intelligence in enhancing patient care and outcomes and has built relevant capabilities within its portfolio companies. For early cancer diagnostics, AI resources were pooled in x-diagnostics, which can now unleash its full potential in a clinical context through the transaction. By becoming a new major shareholder in 4D Lifetec, Xlife Sciences adds a leading early cancer diagnostics pioneer to its portfolio network.

Bringing these two technologies together will enable 4D Lifetec to seamlessly integrate data from diverse sources, including patient history, genetic information, and imaging, providing comprehensive decision support for oncologists Dr. Arne-Christian Faisst, Co-founder and Chairman of 4D Lifetec says. This will result definitively in more accurate early cancer diagnoses, ultimately enhancing patient care and outcomes.